Merck KGaA (MRK) Given a €104.00 Price Target by UBS Group Analysts

Merck KGaA (FRA:MRK) has been given a €104.00 ($120.93) target price by equities researchers at UBS Group in a note issued to investors on Monday, Borsen Zeitung reports. The firm presently has a “neutral” rating on the healthcare company’s stock. UBS Group’s price objective suggests a potential upside of 9.15% from the stock’s current price.

A number of other research analysts have also recently issued reports on the stock. Deutsche Bank set a €97.00 ($112.79) target price on shares of Merck KGaA and gave the company a “neutral” rating in a research note on Thursday. Nord/LB set a €80.00 ($93.02) target price on shares of Merck KGaA and gave the company a “sell” rating in a research note on Thursday, January 24th. HSBC set a €96.00 ($111.63) target price on shares of Merck KGaA and gave the company a “neutral” rating in a research note on Monday, March 11th. Sanford C. Bernstein set a €105.00 ($122.09) target price on shares of Merck KGaA and gave the company a “buy” rating in a research note on Thursday, March 7th. Finally, Goldman Sachs Group set a €95.00 ($110.47) target price on shares of Merck KGaA and gave the company a “neutral” rating in a research note on Tuesday, February 12th. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of €100.95 ($117.38).

FRA:MRK opened at €95.28 ($110.79) on Monday. Merck KGaA has a 1 year low of €76.60 ($89.07) and a 1 year high of €115.00 ($133.72).

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

See Also: What is the formula for the cash asset ratio?

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.